nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—ABCC2—Vincristine—peripheral nervous system neoplasm	0.146	0.288	CbGbCtD
Olmesartan—ABCC2—Cisplatin—peripheral nervous system neoplasm	0.136	0.268	CbGbCtD
Olmesartan—ABCC2—Etoposide—peripheral nervous system neoplasm	0.133	0.264	CbGbCtD
Olmesartan—ABCC2—Doxorubicin—peripheral nervous system neoplasm	0.091	0.18	CbGbCtD
Olmesartan—AGTR1—ACE Inhibitor Pathway—KNG1—peripheral nervous system neoplasm	0.00212	0.0692	CbGpPWpGaD
Olmesartan—ABCC2—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00207	0.0678	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 trafficking events—NME1—peripheral nervous system neoplasm	0.002	0.0655	CbGpPWpGaD
Olmesartan—SLCO1B1—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00195	0.0636	CbGpPWpGaD
Olmesartan—ABCC2—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.00176	0.0575	CbGpPWpGaD
Olmesartan—SLCO1B1—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.00165	0.054	CbGpPWpGaD
Olmesartan—Telmisartan—ABCB1—peripheral nervous system neoplasm	0.0012	0.43	CrCbGaD
Olmesartan—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.00113	0.0371	CbGpPWpGaD
Olmesartan—SLCO1B1—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.00107	0.0348	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 signaling events—HGF—peripheral nervous system neoplasm	0.00099	0.0324	CbGpPWpGaD
Olmesartan—Candesartan—ABCB1—peripheral nervous system neoplasm	0.000967	0.347	CrCbGaD
Olmesartan—AGTR1—Arf6 signaling events—MET—peripheral nervous system neoplasm	0.000781	0.0255	CbGpPWpGaD
Olmesartan—AGTR1—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000692	0.0226	CbGpPWpGaD
Olmesartan—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000684	0.0224	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.000684	0.0223	CbGpPWpGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000652	0.0213	CbGpPWpGaD
Olmesartan—Losartan—ABCB1—peripheral nervous system neoplasm	0.000623	0.223	CrCbGaD
Olmesartan—ABCC2—ABC-family proteins mediated transport—ABCB1—peripheral nervous system neoplasm	0.000622	0.0203	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000619	0.0202	CbGpPWpGaD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PTPN11—peripheral nervous system neoplasm	0.000543	0.0177	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—ABCB1—peripheral nervous system neoplasm	0.000532	0.0174	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000458	0.015	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000349	0.0114	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000343	0.0112	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000335	0.0109	CbGpPWpGaD
Olmesartan—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000332	0.000721	CcSEcCtD
Olmesartan—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000332	0.000721	CcSEcCtD
Olmesartan—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.00033	0.000716	CcSEcCtD
Olmesartan—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.00033	0.000716	CcSEcCtD
Olmesartan—Face oedema—Doxorubicin—peripheral nervous system neoplasm	0.000329	0.000715	CcSEcCtD
Olmesartan—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000329	0.000714	CcSEcCtD
Olmesartan—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000327	0.000711	CcSEcCtD
Olmesartan—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000327	0.000711	CcSEcCtD
Olmesartan—Nausea—Topotecan—peripheral nervous system neoplasm	0.000327	0.00071	CcSEcCtD
Olmesartan—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000326	0.000709	CcSEcCtD
Olmesartan—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000325	0.000706	CcSEcCtD
Olmesartan—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000325	0.000705	CcSEcCtD
Olmesartan—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000325	0.000705	CcSEcCtD
Olmesartan—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000323	0.000702	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000322	0.000698	CcSEcCtD
Olmesartan—Infection—Etoposide—peripheral nervous system neoplasm	0.000321	0.000697	CcSEcCtD
Olmesartan—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000321	0.000696	CcSEcCtD
Olmesartan—Nausea—Melphalan—peripheral nervous system neoplasm	0.00032	0.000696	CcSEcCtD
Olmesartan—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.000694	CcSEcCtD
Olmesartan—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000319	0.000692	CcSEcCtD
Olmesartan—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000317	0.000687	CcSEcCtD
Olmesartan—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000316	0.000685	CcSEcCtD
Olmesartan—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.000316	0.000685	CcSEcCtD
Olmesartan—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000316	0.000685	CcSEcCtD
Olmesartan—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000316	0.000685	CcSEcCtD
Olmesartan—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000314	0.000682	CcSEcCtD
Olmesartan—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000313	0.000679	CcSEcCtD
Olmesartan—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.000313	0.000678	CcSEcCtD
Olmesartan—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000312	0.000677	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000311	0.0102	CbGpPWpGaD
Olmesartan—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000311	0.000674	CcSEcCtD
Olmesartan—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.00031	0.000674	CcSEcCtD
Olmesartan—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000308	0.000669	CcSEcCtD
Olmesartan—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000307	0.000667	CcSEcCtD
Olmesartan—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000307	0.000667	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.000307	0.01	CbGpPWpGaD
Olmesartan—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000307	0.000666	CcSEcCtD
Olmesartan—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000307	0.000665	CcSEcCtD
Olmesartan—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000306	0.000664	CcSEcCtD
Olmesartan—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000305	0.000662	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000305	0.000661	CcSEcCtD
Olmesartan—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.000303	0.000657	CcSEcCtD
Olmesartan—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000302	0.000656	CcSEcCtD
Olmesartan—Pain—Cisplatin—peripheral nervous system neoplasm	0.000302	0.000655	CcSEcCtD
Olmesartan—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000301	0.000653	CcSEcCtD
Olmesartan—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000298	0.000647	CcSEcCtD
Olmesartan—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000297	0.000645	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000296	0.000643	CcSEcCtD
Olmesartan—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000295	0.00064	CcSEcCtD
Olmesartan—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000293	0.000636	CcSEcCtD
Olmesartan—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.000292	0.000634	CcSEcCtD
Olmesartan—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000291	0.000632	CcSEcCtD
Olmesartan—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000291	0.000631	CcSEcCtD
Olmesartan—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000289	0.000628	CcSEcCtD
Olmesartan—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000288	0.000624	CcSEcCtD
Olmesartan—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.000624	CcSEcCtD
Olmesartan—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000286	0.000622	CcSEcCtD
Olmesartan—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000286	0.00062	CcSEcCtD
Olmesartan—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000617	CcSEcCtD
Olmesartan—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000617	CcSEcCtD
Olmesartan—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000284	0.000617	CcSEcCtD
Olmesartan—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000284	0.000616	CcSEcCtD
Olmesartan—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000283	0.000615	CcSEcCtD
Olmesartan—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000282	0.000611	CcSEcCtD
Olmesartan—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000281	0.00061	CcSEcCtD
Olmesartan—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.00028	0.000608	CcSEcCtD
Olmesartan—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000279	0.000606	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000279	0.000606	CcSEcCtD
Olmesartan—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000279	0.000606	CcSEcCtD
Olmesartan—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000279	0.000605	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000278	0.00909	CbGpPWpGaD
Olmesartan—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000277	0.000601	CcSEcCtD
Olmesartan—Constipation—Etoposide—peripheral nervous system neoplasm	0.000277	0.0006	CcSEcCtD
Olmesartan—Pain—Etoposide—peripheral nervous system neoplasm	0.000277	0.0006	CcSEcCtD
Olmesartan—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000276	0.0006	CcSEcCtD
Olmesartan—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000276	0.000599	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000274	0.000595	CcSEcCtD
Olmesartan—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000274	0.000595	CcSEcCtD
Olmesartan—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000273	0.000593	CcSEcCtD
Olmesartan—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000588	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	0.00027	0.00883	CbGpPWpGaD
Olmesartan—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000584	CcSEcCtD
Olmesartan—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000267	0.000579	CcSEcCtD
Olmesartan—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000266	0.000578	CcSEcCtD
Olmesartan—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000266	0.000577	CcSEcCtD
Olmesartan—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000265	0.000576	CcSEcCtD
Olmesartan—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000265	0.000576	CcSEcCtD
Olmesartan—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000265	0.000574	CcSEcCtD
Olmesartan—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000264	0.000574	CcSEcCtD
Olmesartan—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000264	0.000573	CcSEcCtD
Olmesartan—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000263	0.000572	CcSEcCtD
Olmesartan—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000571	CcSEcCtD
Olmesartan—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000571	CcSEcCtD
Olmesartan—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000261	0.000567	CcSEcCtD
Olmesartan—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000261	0.000566	CcSEcCtD
Olmesartan—Headache—Alitretinoin—peripheral nervous system neoplasm	0.00026	0.000563	CcSEcCtD
Olmesartan—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000259	0.000561	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000257	0.00841	CbGpPWpGaD
Olmesartan—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000257	0.000558	CcSEcCtD
Olmesartan—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000256	0.000556	CcSEcCtD
Olmesartan—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000256	0.000555	CcSEcCtD
Olmesartan—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000256	0.000555	CcSEcCtD
Olmesartan—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000256	0.000555	CcSEcCtD
Olmesartan—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000256	0.000555	CcSEcCtD
Olmesartan—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000254	0.000551	CcSEcCtD
Olmesartan—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000253	0.00055	CcSEcCtD
Olmesartan—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000253	0.00055	CcSEcCtD
Olmesartan—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000252	0.000547	CcSEcCtD
Olmesartan—Rash—Vincristine—peripheral nervous system neoplasm	0.000252	0.000546	CcSEcCtD
Olmesartan—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000251	0.000546	CcSEcCtD
Olmesartan—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000251	0.000546	CcSEcCtD
Olmesartan—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.000544	CcSEcCtD
Olmesartan—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000251	0.000544	CcSEcCtD
Olmesartan—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.00025	0.000543	CcSEcCtD
Olmesartan—Headache—Vincristine—peripheral nervous system neoplasm	0.00025	0.000543	CcSEcCtD
Olmesartan—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000247	0.000536	CcSEcCtD
Olmesartan—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000246	0.000534	CcSEcCtD
Olmesartan—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000245	0.000533	CcSEcCtD
Olmesartan—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000242	0.000524	CcSEcCtD
Olmesartan—Nausea—Vincristine—peripheral nervous system neoplasm	0.000237	0.000515	CcSEcCtD
Olmesartan—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000237	0.000514	CcSEcCtD
Olmesartan—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000234	0.000509	CcSEcCtD
Olmesartan—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000233	0.000506	CcSEcCtD
Olmesartan—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000233	0.000505	CcSEcCtD
Olmesartan—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000232	0.000504	CcSEcCtD
Olmesartan—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000232	0.000504	CcSEcCtD
Olmesartan—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000231	0.000502	CcSEcCtD
Olmesartan—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.000502	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00023	0.00753	CbGpPWpGaD
Olmesartan—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00023	0.000499	CcSEcCtD
Olmesartan—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000229	0.000497	CcSEcCtD
Olmesartan—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000495	CcSEcCtD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000227	0.00741	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000226	0.00739	CbGpPWpGaD
Olmesartan—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000225	0.000489	CcSEcCtD
Olmesartan—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000224	0.000487	CcSEcCtD
Olmesartan—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000224	0.000485	CcSEcCtD
Olmesartan—Rash—Cisplatin—peripheral nervous system neoplasm	0.000223	0.000483	CcSEcCtD
Olmesartan—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000222	0.000483	CcSEcCtD
Olmesartan—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000222	0.000482	CcSEcCtD
Olmesartan—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000221	0.00048	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000218	0.00711	CbGpPWpGaD
Olmesartan—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000215	0.000466	CcSEcCtD
Olmesartan—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000214	0.000465	CcSEcCtD
Olmesartan—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000214	0.000464	CcSEcCtD
Olmesartan—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000463	CcSEcCtD
Olmesartan—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000213	0.000462	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—peripheral nervous system neoplasm	0.000211	0.00689	CbGpPWpGaD
Olmesartan—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000458	CcSEcCtD
Olmesartan—Nausea—Cisplatin—peripheral nervous system neoplasm	0.00021	0.000455	CcSEcCtD
Olmesartan—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000209	0.000454	CcSEcCtD
Olmesartan—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000209	0.000453	CcSEcCtD
Olmesartan—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000449	CcSEcCtD
Olmesartan—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000206	0.000447	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000206	0.00673	CbGpPWpGaD
Olmesartan—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000206	0.000446	CcSEcCtD
Olmesartan—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000206	0.000446	CcSEcCtD
Olmesartan—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000205	0.000446	CcSEcCtD
Olmesartan—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000204	0.000443	CcSEcCtD
Olmesartan—Rash—Etoposide—peripheral nervous system neoplasm	0.000204	0.000443	CcSEcCtD
Olmesartan—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000204	0.000442	CcSEcCtD
Olmesartan—Headache—Etoposide—peripheral nervous system neoplasm	0.000203	0.00044	CcSEcCtD
Olmesartan—Malaise—Epirubicin—peripheral nervous system neoplasm	0.0002	0.000435	CcSEcCtD
Olmesartan—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.0002	0.000433	CcSEcCtD
Olmesartan—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000199	0.000432	CcSEcCtD
Olmesartan—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000199	0.000432	CcSEcCtD
Olmesartan—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000431	CcSEcCtD
Olmesartan—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000429	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000197	0.00645	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000197	0.00644	CbGpPWpGaD
Olmesartan—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000196	0.000426	CcSEcCtD
Olmesartan—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000195	0.000424	CcSEcCtD
Olmesartan—Cough—Epirubicin—peripheral nervous system neoplasm	0.000194	0.000421	CcSEcCtD
Olmesartan—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000194	0.00042	CcSEcCtD
Olmesartan—Nausea—Etoposide—peripheral nervous system neoplasm	0.000192	0.000417	CcSEcCtD
Olmesartan—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000191	0.000414	CcSEcCtD
Olmesartan—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.000412	CcSEcCtD
Olmesartan—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000189	0.00041	CcSEcCtD
Olmesartan—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000189	0.00041	CcSEcCtD
Olmesartan—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000189	0.00041	CcSEcCtD
Olmesartan—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000189	0.00041	CcSEcCtD
Olmesartan—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000188	0.000409	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000188	0.000408	CcSEcCtD
Olmesartan—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000187	0.000406	CcSEcCtD
Olmesartan—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.000402	CcSEcCtD
Olmesartan—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.000401	CcSEcCtD
Olmesartan—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000184	0.0004	CcSEcCtD
Olmesartan—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000184	0.000399	CcSEcCtD
Olmesartan—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000394	CcSEcCtD
Olmesartan—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000393	CcSEcCtD
Olmesartan—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000393	CcSEcCtD
Olmesartan—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000392	CcSEcCtD
Olmesartan—Infection—Epirubicin—peripheral nervous system neoplasm	0.00018	0.000391	CcSEcCtD
Olmesartan—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000179	0.000389	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000179	0.00586	CbGpPWpGaD
Olmesartan—Shock—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000387	CcSEcCtD
Olmesartan—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000386	CcSEcCtD
Olmesartan—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000385	CcSEcCtD
Olmesartan—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000384	CcSEcCtD
Olmesartan—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000176	0.000382	CcSEcCtD
Olmesartan—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000175	0.00038	CcSEcCtD
Olmesartan—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.00038	CcSEcCtD
Olmesartan—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.00038	CcSEcCtD
Olmesartan—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.00038	CcSEcCtD
Olmesartan—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000174	0.000378	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000174	0.000377	CcSEcCtD
Olmesartan—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.000375	CcSEcCtD
Olmesartan—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000173	0.000375	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000172	0.00561	CbGpPWpGaD
Olmesartan—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000368	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000169	0.00553	CbGpPWpGaD
Olmesartan—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000364	CcSEcCtD
Olmesartan—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000364	CcSEcCtD
Olmesartan—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.000362	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000165	0.000358	CcSEcCtD
Olmesartan—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.000358	CcSEcCtD
Olmesartan—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000357	CcSEcCtD
Olmesartan—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000356	CcSEcCtD
Olmesartan—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000164	0.000356	CcSEcCtD
Olmesartan—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000355	CcSEcCtD
Olmesartan—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.000354	CcSEcCtD
Olmesartan—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000352	CcSEcCtD
Olmesartan—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000347	CcSEcCtD
Olmesartan—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.00016	0.000346	CcSEcCtD
Olmesartan—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000342	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000157	0.00513	CbGpPWpGaD
Olmesartan—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.00034	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000156	0.00034	CcSEcCtD
Olmesartan—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000156	0.000339	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000156	0.00509	CbGpPWpGaD
Olmesartan—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000336	CcSEcCtD
Olmesartan—Pain—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000336	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000332	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000153	0.00499	CbGpPWpGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000152	0.00498	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000152	0.00497	CbGpPWpGaD
Olmesartan—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000152	0.000329	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.00015	0.00489	CbGpPWpGaD
Olmesartan—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000149	0.000324	CcSEcCtD
Olmesartan—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000148	0.000322	CcSEcCtD
Olmesartan—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.00032	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000146	0.00478	CbGpPWpGaD
Olmesartan—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000316	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000314	CcSEcCtD
Olmesartan—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000314	CcSEcCtD
Olmesartan—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000313	CcSEcCtD
Olmesartan—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000311	CcSEcCtD
Olmesartan—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000311	CcSEcCtD
Olmesartan—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000311	CcSEcCtD
Olmesartan—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000311	CcSEcCtD
Olmesartan—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000138	0.0003	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000137	0.00448	CbGpPWpGaD
Olmesartan—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.000298	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000136	0.00444	CbGpPWpGaD
Olmesartan—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000289	CcSEcCtD
Olmesartan—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000288	CcSEcCtD
Olmesartan—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000288	CcSEcCtD
Olmesartan—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000282	CcSEcCtD
Olmesartan—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000278	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000127	0.00415	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000125	0.0041	CbGpPWpGaD
Olmesartan—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000269	CcSEcCtD
Olmesartan—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000261	CcSEcCtD
Olmesartan—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.00012	0.00026	CcSEcCtD
Olmesartan—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000258	CcSEcCtD
Olmesartan—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000115	0.00025	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000115	0.00376	CbGpPWpGaD
Olmesartan—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000249	CcSEcCtD
Olmesartan—Rash—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000248	CcSEcCtD
Olmesartan—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000248	CcSEcCtD
Olmesartan—Headache—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000246	CcSEcCtD
Olmesartan—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000241	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—GNS—peripheral nervous system neoplasm	0.00011	0.00361	CbGpPWpGaD
Olmesartan—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000234	CcSEcCtD
Olmesartan—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000231	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—NME1—peripheral nervous system neoplasm	0.000106	0.00346	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000106	0.00346	CbGpPWpGaD
Olmesartan—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.00023	CcSEcCtD
Olmesartan—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000229	CcSEcCtD
Olmesartan—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000228	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000103	0.00335	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—COX2—peripheral nervous system neoplasm	0.000102	0.00333	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000102	0.00332	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000101	0.00332	CbGpPWpGaD
Olmesartan—Nausea—Doxorubicin—peripheral nervous system neoplasm	9.96e-05	0.000216	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	9.27e-05	0.00303	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	9.09e-05	0.00297	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	8.87e-05	0.0029	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	8.53e-05	0.00279	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	8.24e-05	0.00269	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	8.05e-05	0.00263	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	8.02e-05	0.00262	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	7.75e-05	0.00253	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	7.74e-05	0.00253	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	7.44e-05	0.00243	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GNS—peripheral nervous system neoplasm	7.42e-05	0.00243	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	7.4e-05	0.00242	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NME1—peripheral nervous system neoplasm	7.11e-05	0.00233	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	7.04e-05	0.0023	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—COX2—peripheral nervous system neoplasm	6.85e-05	0.00224	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ENO2—peripheral nervous system neoplasm	6.69e-05	0.00219	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	6.63e-05	0.00217	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	6.5e-05	0.00213	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	6.23e-05	0.00203	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	6.11e-05	0.002	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—BCHE—peripheral nervous system neoplasm	5.65e-05	0.00185	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.56e-05	0.00182	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.39e-05	0.00176	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—TH—peripheral nervous system neoplasm	5.32e-05	0.00174	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.89e-05	0.0016	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.76e-05	0.00155	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.53e-05	0.00148	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ENO2—peripheral nervous system neoplasm	4.5e-05	0.00147	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GNAS—peripheral nervous system neoplasm	4.34e-05	0.00142	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ABCB1—peripheral nervous system neoplasm	4.26e-05	0.00139	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.16e-05	0.00136	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—BCHE—peripheral nervous system neoplasm	3.8e-05	0.00124	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.62e-05	0.00118	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—TH—peripheral nervous system neoplasm	3.57e-05	0.00117	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.94e-05	0.000961	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GNAS—peripheral nervous system neoplasm	2.92e-05	0.000953	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.89e-05	0.000944	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ABCB1—peripheral nervous system neoplasm	2.86e-05	0.000935	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.28e-05	0.000746	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.15e-05	0.000703	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.09e-05	0.000684	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.07e-05	0.000678	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.9e-05	0.000621	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.74e-05	0.000568	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.62e-05	0.000529	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.33e-05	0.000434	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.27e-05	0.000415	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—AKT1—peripheral nervous system neoplasm	1.17e-05	0.000383	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.12e-05	0.000367	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—AKT1—peripheral nervous system neoplasm	7.87e-06	0.000257	CbGpPWpGaD
